Please assess the completion status of the following clinical trial:

Trial Title: Levosimendan Versus Dobutamine for Renal Function in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written, signed and dated informed consent~* Male and Female subjects ≥18 years of age~* Chronic congestive heart failure scheduled for right sided cardiac catheterization~* Left ventricular ejection fraction ≤ 40% determined by echocardiography~* Elevation of N Terminal-proBNP ≥ 500 ng/L~* Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)~Exclusion Criteria:~* Acute heart failure, untreated~* Systolic blood pressure \< 80 mmHg~* Tachycardia above 100 bpm~* Angina Canadian Cardiovascular Society (CCS) class III or higher~* Aortic stenosis~* Hypertrophic cardiomyopathy~* Restrictive cardiomyopathy~* The presence of kidney disease diagnosed before heart failure~* Administration of radiographic contrast \< 1 week~* Radiographic contrast allergy~* In the Investigator's opinion, the patient has a clinically significant disease that could be adversely affected by study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levosimendan (Type: ACTIVE_COMPARATOR): Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
- Dobutamine (Type: ACTIVE_COMPARATOR): Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.

Based on this trial design, predict the completion outcome and termination type (if applicable).